Eli Lilly

Antibody drug conjugate
#Antibody drug conjugate (ADC) #CrossBridge Bio #Eli Lilly #Mergers and acquisitions

Antibody-drug conjugate company CrossBridge Bio acquired by Lilly

Eli Lilly has signed a definitive agreement to acquire preclinical biotechnology company CrossBridge Bio for up to $300 million in cash, inclusive of an upfront payment and a subsequent milestone-dependent payment.  CrossBridge Bio, a Houston-based biotechnology firm founded in 2023, is developing a new dual-payload ADC technology originally created by… Read More

#Business & Investment #News

Cardiovascular system
#Diabetes #Eli Lilly #Obesity #Phase III trial #Weight loss

Lilly publishes data confirming Foundayo’s safety profile

Eli Lilly has shared positive topline results from the Phase III ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.   ACHIEVE-4, the largest and longest study of Foundayo… Read More

#News

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

DDW Highlights: 14 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Eli… Read More

#Podcasts

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

This week in Drug Discovery (6 – 10 April) 

News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW.  This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration.  The top stories: … Read More

#News

Lilly Biotechnology Center
#AC Immune #Alzheimer's #Eli Lilly

AC Immune and Lilly reach agreement on drug collaboration 

Biopharmaceutical company AC Immune has reached an amended agreement with Eli Lilly for the development of an Alzheimer’s treatment.  The amendment to the 2018 license includes an agreement on the collaboration to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative… Read More

#Business & Investment #News

Pills
#Eli Lilly #FDA #GLP-1 #Obesity #Weight loss

FDA approves Lilly’s GLP-1 pill for weight loss

The US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.   "People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water… Read More

#News #Regulatory #Trending News

#AI / data analytics / healthtech / informatics #ALS #Alzheimer's #Axol Bioscience #Biologics #Centessa Pharmaceuticals #Corcept Therapeutics #Denali Therapeutics #Eli Lilly #FDA #Hunter Syndrome #LifeArc #Mergers and acquisitions #MND #Ovarian cancer #Stanford University

DDW Highlights: 7 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More

#Podcasts

Narcolepsy
#Centessa Pharmaceuticals #Eli Lilly #Mergers and acquisitions

Lilly acquires sleep-wake disorders specialist Centessa

Eli Lilly has announced a definitive agreement under which it will acquire Centessa Pharmaceuticals for approximately $6.3 billion upfront and a potential equity value of $1.5 billion.  Centessa is developing a pipeline of orexin receptor 2 (OX2R) agonists designed to address the neurobiological system critical to the sleep-wake cycle to… Read More

#Business & Investment #News

Automation and robotics
#Artificial intelligence (AI) #Eli Lilly #Insilico Medicine

Eli Lilly and Insilico agree AI-driven drug discovery alliance

Eli Lilly and Insilico Medicine have announced a drug discovery collaboration that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.  The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialisation of potentially best-in-class, novel oral therapeutics in… Read More

#Business & Investment #News

Obese man measures his waist
#Diabetes #Eli Lilly #GLP-1 #Obesity #Phase III trial

Lilly’s triple agonist significantly reduces A1C and weight

Eli Lilly has announced positive topline results from TRANSCEND-T2D-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise.   The trial enrolled adults diagnosed with type 2… Read More

#News

Lilly Biotechnology Center
#Alzheimer's #Eli Lilly #National Institute for Health and Care Excellence (NICE) #NHS

Lilly wins appeal for donanemab, drug to be reconsidered for NHS 

Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use.  The National Institute for Health and Care Excellence (NICE) published the outcome for Lilly’s appeal, after final draft guidance had not recommended NHS reimbursement of donanemab for the treatment of mild cognitive… Read More

#News

#Advanced Therapies #Autoimmune disease #Cell therapy #Eli Lilly #Orna Therapeutics

Lilly to advance cell therapies after Orna acquisition 

Eli Lilly has acquired biotech company Orna Therapeutics to further develop its pipeline of cell therapies in autoimmune diseases.  Orna is advancing a new class of therapeutics utilising engineered circular RNA paired with novel lipid nanoparticles to allow the patient’s own body to generate cell therapies that can treat underlying disease.  The company’s lead programme,… Read More

#Business & Investment #News

#AbbVie #Cell and gene therapy #CRISPR Therapeutics #Eli Lilly #Hansa Biopharma #Resolution Therapeutics #Vertex

Cell and gene therapies – looking forward

Drug Discovery World speaks to key players in the cell and gene therapy sector to learn about the opportunities and challenges in this promising but difficult treatment area.      Developers of cell and gene therapies (CGTs) have had a difficult few years. Despite the undoubted promise of exciting new technologies in this area to… Read More

#Exclusive Content

#Advanced Therapies #Collaboration #Eli Lilly #Gene editing #Hearing Loss #Seamless Therapeutics

Lilly’s Seamless gene editing collaboration targets hearing loss

Eli Lilly and Seamless Therapeutics are teaming up to develop and commercialise programmable recombinase-based treatments targeting hearing loss indications, using Seamless’ proprietary recombinase platform.   The company’s technology performs large, precise DNA insertions in any target gene sequence, and operates independent of the cell’s natural DNA repair pathway.  Under the… Read More

#Business & Investment #News

Lilly Biotechnology Center
#Acute inflammatory conditions #Cardiometabolic diseases #Eli Lilly #Mergers and acquisitions #Neurodegenerative disorders #Ventyx Biosciences

Lilly acquires Ventyx Biosciences for $1.2 billion

Eli Lilly has agreed to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on developing oral therapies for patients with inflammatory-mediated diseases.  Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across a broad range of disease states with high unmet need.   These… Read More

#Business & Investment #News

Overweight man clutching his knee
#Arthritis #Eli Lilly #Monoclonal antibodies #Obesity #Phase III trial #Weight loss

Combination therapy moves the needle in arthritis and obesity

Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together have been shown to deliver superior efficacy in first-of-its-kind Phase IIIb trial for adults with active psoriatic arthritis (PsA) and obesity or who are overweight.  At 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all… Read More

#News #Trending News